CASI Valuation

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

CASI Relative Valuation

CASI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CASI is overvalued; if below, it's undervalued.

Historical Valuation

CASI Pharmaceuticals Inc (CASI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.93 is considered Undervalued compared with the five-year average of -3.95. The fair price of CASI Pharmaceuticals Inc (CASI) is between 4.56 to 5.39 according to relative valuation methord. Compared to the current price of 2.26 USD , CASI Pharmaceuticals Inc is Undervalued By 50.44%.

Relative Value

Fair Zone

4.56-5.39

Current Price：2.26

50.44%

Undervalued

-1.21

Trailing

Forward

0.00

EV/EBITDA

CASI Pharmaceuticals Inc. (CASI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.09. The thresholds are as follows: Strongly Undervalued below -9.29, Undervalued between -9.29 and -5.69, Fairly Valued between 1.51 and -5.69, Overvalued between 1.51 and 5.11, and Strongly Overvalued above 5.11. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.34

EV/EBIT

CASI Pharmaceuticals Inc. (CASI) has a current EV/EBIT of -1.34. The 5-year average EV/EBIT is -2.81. The thresholds are as follows: Strongly Undervalued below -8.02, Undervalued between -8.02 and -5.42, Fairly Valued between -0.21 and -5.42, Overvalued between -0.21 and 2.40, and Strongly Overvalued above 2.40. The current Forward EV/EBIT of -1.34 falls within the Historic Trend Line -Fairly Valued range.

3.93

CASI Pharmaceuticals Inc. (CASI) has a current PS of 3.93. The 5-year average PS is 3.74. The thresholds are as follows: Strongly Undervalued below -4.60, Undervalued between -4.60 and -0.43, Fairly Valued between 7.91 and -0.43, Overvalued between 7.91 and 12.08, and Strongly Overvalued above 12.08. The current Forward PS of 3.93 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

CASI Pharmaceuticals Inc. (CASI) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.74. The thresholds are as follows: Strongly Undervalued below -10.26, Undervalued between -10.26 and -6.50, Fairly Valued between 1.02 and -6.50, Overvalued between 1.02 and 4.78, and Strongly Overvalued above 4.78. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

CASI Pharmaceuticals Inc. (CASI) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.03. The thresholds are as follows: Strongly Undervalued below -8.26, Undervalued between -8.26 and -5.14, Fairly Valued between 1.09 and -5.14, Overvalued between 1.09 and 4.21, and Strongly Overvalued above 4.21. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

CASI Pharmaceuticals Inc (CASI) has a current Price-to-Book (P/B) ratio of -4.57. Compared to its 3-year average P/B ratio of 2.68 , the current P/B ratio is approximately -270.19% higher. Relative to its 5-year average P/B ratio of 2.45, the current P/B ratio is about -286.79% higher. CASI Pharmaceuticals Inc (CASI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -28.07%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -27.81% , the current FCF yield is about -100.00% lower.

-4.57

P/B

Median3y

2.68

Median5y

2.45

0.00

FCF Yield

Median3y

-28.07

Median5y

-27.81

Competitors Valuation Multiple

The average P/S ratio for CASI's competitors is 30.35, providing a benchmark for relative valuation. CASI Pharmaceuticals Inc Corp (CASI) exhibits a P/S ratio of 3.93, which is -87.06% above the industry average. Given its robust revenue growth of 83.04%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CASI.O

CASI Pharmaceuticals Inc

Xilio Therapeutics Inc

Reviva Pharmaceuticals Holdings Inc

Performance Decomposition

Market capitalization of CASI decreased by 65.71% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.41M to 6.24M.

The secondary factor is the Margin Expansion, contributed -38.37%to the performance.

Overall, the performance of CASI in the past 1 year is driven by Revenue Growth. Which is more sustainable.

83.04%

3.41M → 6.24M

Revenue Growth

-38.37%

-279.52 → -172.28

Margin Expansion

-110.38%

8.99 → -0.93

P/E Change

-65.71%